Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2018-03-26FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) from Merck Sharp & Dohme LLC.
-
FDA approval · 2018-03-23FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Teva Parenteral Medicines, Inc.)
FDA approved Teva Parenteral Medicines' palonosetron hydrochloride injection as an original application (ANDA 090713), establishing bioequiv…
-
FDA approval · 2018-03-14FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Chartwell RX, LLC.)
FDA approved a supplemental application for ondansetron hydrochloride from Chartwell RX, LLC, under the ANDA process.
-
CLINICAL_TRIALS trial_result · 2018-03-08Clinical Trial Update: Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044) [Phase 3]
Phase 3 trial evaluating fosaprepitant with ondansetron versus ondansetron alone for preventing chemotherapy-induced nausea and vomiting in …
-
FDA approval · 2018-03-07FDA Approved: ONDANSETRON — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for ondansetron under an ANDA held by PAI Holdings dba PAI Pharma, indicating a supplemental reg…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2018-03-07FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Aurobindo Pharma Limited, granting approval of this generic p…
-
FDA approval · 2018-03-07FDA Approved: ONDANSETRON — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for ondansetron hydrochloride (ONDANSETRON) from NorthStar Rx LLC, resulting in updated labeling for…
-
FDA approval · 2018-03-07FDA Approved: ONDANSETRON — Supplemental Application (Rising Pharma Holdings, Inc.)
FDA approved a supplemental application for ondansetron from Rising Pharma Holdings, Inc., marking an update to the generic's labeling or po…
-
FDA label_change · 2018-03-07FDA Approved: ONDANSETRON — Supplemental Application (AvPAK)
FDA listing shows a supplemental application for ondansetron by AvPAK, likely related to changes to labeling or approved indications for thi…
-
FDA approval · 2018-02-26FDA Approved: ONDANSETRON — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for ondansetron filed by Chartwell RX, LLC.
-
FDA approval · 2018-02-26FDA Approved: ONDANSETRON — Supplemental Application (Chartwell RX, LLC)
The FDA approved a supplemental application for ondansetron submitted by Chartwell RX, LLC, approving a generic ondansetron product.
-
FDA approval · 2018-02-13FDA Approved: ONDANSETRON — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
FDA approved a supplemental application for ondansetron submitted by Glenmark Pharmaceuticals Inc., USA.
-
FDA approval · 2018-02-13FDA Approved: ONDANSETRON — Supplemental Application (AvKARE)
FDA approved a supplemental application for AvKARE's ondansetron, a generic antiemetic, indicating an addition or modification to the approv…
-
CLINICAL_TRIALS trial_result · 2018-01-17Clinical Trial Update: A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting. [Phase 3]
Phase 3 trial update for IV casopitant aiming to prevent chemotherapy-induced nausea and vomiting; study completed with results posted in 20…
-
CLINICAL_TRIALS trial_result · 2017-11-21Clinical Trial Update: Study of the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children (MK-0517-029) [Phase 2]
Phase 2 clinical trial evaluating pharmacokinetics, pharmacodynamics, safety, and tolerability of fosaprepitant for preventing chemotherapy-…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects [Phase 1]
Phase 1 study evaluating the effect of intravenous ondansetron on cardiac conduction compared with placebo and moxifloxacin in healthy adult…
-
CLINICAL_TRIALS trial_result · 2017-11-13Clinical Trial Update: A Study to Assess the Safety & Interaction Between GW679769, Dexamethasone, & Ondansetron When Taken by Healthy Adults [Phase 1]
This clinical trial update reports the completion of a Phase 1 study evaluating safety and potential interactions among GW679769, dexamethas…
-
FDA approval · 2017-11-09FDA Approved: CINVANTI — Original Application (Heron Therapeutics, Inc.)
The FDA approved CINVANTI (aprepitant) under an original NDA from Heron Therapeutics for preventing chemotherapy-induced nausea and vomiting…
-
FDA approval · 2017-10-12FDA Approved: APREPITANT — Original Application (BluePoint Laboratories)
FDA approved the original application for a generic aprepitant (APREPITANT) from BluePoint Laboratories, confirming a generic version of the…
-
FDA approval · 2017-09-13FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved Cumberland Pharmaceuticals' supplemental application for SANCUSO (granisetron). The granisetron product is used to prevent chem…
-
FDA approval · 2017-08-28FDA Approved: DRONABINOL — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for dronabinol from Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2017-08-22Clinical Trial Update: A Study of the Drug Casopitant for the Prevention of Nausea Caused By Cisplatin-Based Highly Emetogenic Chemotherapy [Phase 3]
A Phase 3 trial evaluating casopitant to prevent nausea and vomiting caused by cisplatin-based chemotherapy has completed.
-
FDA approval · 2017-08-09FDA Approved: EMEND — Supplemental Application (Merck Sharp & Dohme LLC)
The FDA approved a supplemental application for EMEND (fosaprepitant dimeglumine) submitted by Merck Sharp & Dohme LLC.
-
CLINICAL_TRIALS trial_result · 2017-08-09Clinical Trial Update: A Study Testing the Effect and Safety of Casopitant (GW679769) While Taking Warfarin in Healthy Human Volunteers [Phase 1]
A Phase 1 study evaluated the effect and safety of the antiemetic casopitant (GW679769) when co-administered with warfarin in healthy volunt…
-
CLINICAL_TRIALS trial_result · 2017-08-04Clinical Trial Update: The Effects Of GW679769 (Casopitant) On The Pharmacokinetics Of Docetaxel In Subjects With Cancer [Phase 1]
Phase 1 study evaluating the pharmacokinetic interaction between casopitant and docetaxel in cancer patients; the trial is completed.